Home・Listă Acțiuni・Editas Medicine Inc

Editas Medicine Inc

Închisă

SectorSănătate

2.86

Cumpără Vinde

Rezumat

Modificarea prețului

24h

Curent

Minim

2.81

Maxim

3.02

Indicatori cheie
By Trading Economics
Venit	6.8M -18M
Vânzări	9.1M 12M
EPS	-0.15
Marjă de profit	-153.322
Angajați	87
EBITDA	3.9M -20M

Recomandări
By TipRanks
Recomandări	Cumpărare
Prognoză pe 12 luni	+171.19% upside

Dividende
By Acuity
Următoarele câștiguri	9 nov. 2026

Statistici piață
By TradingEconomics
Capitalizare de piață	25M 432M
Deschiderea anterioară	2.86
Închiderea anterioară	2.86

Sentimentul știrilor

By Acuity

63%

37%

279 / 340 Clasament în Healthcare

Editas Medicine Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

11 aug. 2026, 19:46 UTC

Editas Medicine Inc shares are trading higher today, reflecting unusual strength. No specific company news was identified to explain this price action.

10 aug. 2026, 23:26 UTC

Editas Medicine Inc shares are higher in after-market hours. No specific company news was identified to explain this movement amid broader market uncertainties.

7 aug. 2026, 23:16 UTC

Editas Medicine Inc. shares were little changed in after-market trading, with no specific news identified. The stock remains above its 20-day moving average.

6 aug. 2026, 23:02 UTC

Editas Medicine Inc shares are higher in after-market hours, reflecting positive momentum following a strong trading session despite no specific company news.

5 aug. 2026, 22:02 UTC

News

Editas Medicine reports second-quarter loss of $18.2 million, better than expected. Shares are higher after positive updates on EDIT-401 program and revenue growth.

31 iul. 2026, 19:56 UTC

Correlated Moves

EDIT shares lower amid broader biotech sector decline today.

30 iul. 2026, 23:51 UTC

Editas Medicine Inc shares are lower in after-market trading, continuing a decline since Thursday's close while remaining near the lower end of its one-month range.

29 iul. 2026, 23:46 UTC

Editas Medicine Inc shares are lower in after-market hours, with no specific news identified. The stock remains near its one-month low amid broader market caution.

28 iul. 2026, 20:07 UTC

Editas Medicine Inc shares are trading lower today, continuing a broader trend in the biotechnology sector. The stock remains below its 20-day moving average.

27 iul. 2026, 17:26 UTC

Editas Medicine Inc is trading higher today, following a notable peak. The upward movement comes amid easing inflation concerns from declining oil prices.

24 iul. 2026, 17:46 UTC

Editas Medicine Inc shares are lower today, continuing a trend of declines over the past three sessions amid broader market volatility linked to falling oil prices.

22 iul. 2026, 19:26 UTC

Editas Medicine Inc is lower today, continuing a decline since Tuesday's close. Broader market weakness may be influencing investor sentiment.

21 iul. 2026, 23:11 UTC

Editas Medicine Inc shares are higher in after-market hours, reflecting positive momentum since Tuesday's close, though they remain below their 20-day moving average.

Comparație

Modificare preț

Editas Medicine Inc Așteptări

Obiectiv de preț

By TipRanks

171.19% sus

Prognoză pe 12 luni

Medie 8 USD 171.19%

Maxim 15 USD

Minim 4 USD

În baza a 6 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruEditas Medicine Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

6 ratings

Cumpărare

Păstrare

Vânzare

Ținând cont de 6 analiști care au acordat evaluări ale acțiunilor Editas Medicine Inc - Dist în ultimele 3 luni.

Sentiment

By Acuity

279 / 340 Clasament în Sănătate

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

Despre Editas Medicine Inc

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; collaboration and nonexclusive license agreement with Genevant Sciences to develop Novel mRNA-LNP gene editing therapeuticsand strategic alliance and option agreement with Allergan Pharmaceuticals International Limited, as well as collaboration with Bristol Myers Squibb for research and development of alpha-beta T cell medicines for the treatment of cancer and autoimmune diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.